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Abstract
Background: Human Papillomavirus (HPV) is a DNA virus with more than 100 genotypes, at least 12 of which are high-risk and
associated with high-grade cervical lesions. Data on the prevalence of high-risk HPV genotypes among women are not yet available
for the total regions of Iran.
Objectives: The present study aimed to determine the prevalence of high-risk HPV types among women screened for cervical carci-
noma in Yazd and compare the cytology, histology, and colposcopy results.
Methods: In this cross-sectional study, 402 women referring to gynecology clinics of Shahid Sadoughi University of Medical Sci-
ences, Yazd, Iran, were selected. The Pap smear and HPV typing were performed on cervical samples. The high-risk HPV types were
detected by the polymerase chain reaction (PCR)-based reverse blot hybridization assay. Colposcopy was carried out on patients
with high-risk HPV types, and biopsies were taken for histological examination.
Results: Among 402 women screened by HPV-PCR, 32 (7.97%) women were positive for high-risk HPV types. Human papillomavirus 16
and HPV18 were the most frequent genotypes (46.9%). The cytology, histology, and colposcopy results were abnormal in 56.2%, 29.1%,
and 71.9% of patients, respectively. Pap smear had 100% sensitivity and 58.3% specificity for the detection of high-grade cervical
lesions, while these values for colposcopy were 75% and 87.5%, respectively.
Conclusions: The frequency of high-risk HPV types was relatively low among women living in Yazd than in those from other
provinces of Iran. A significant percentage of patients with HPV had normal cervical cytology and histology. Therefore, HPV typ-
ing is recommended to decrease the development of cervical cancer. Colposcopy had acceptable sensitivity and specificity for the
detection of high-grade cervical lesions.
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1. Background
Cervical cancer is the fourth most frequent malignancy
that affects women. The World Health Organization (WHO)
estimates that 530,000 new cases of cervical cancer are di-
agnosed worldwide that lead to 275,000 death each year
(1). Approximately 90% of deaths are reported from low-
and middle-income countries. The age-standardized rate
(ASR) for cervical cancer in Iran is estimated to be 2.8, and
its mortality is 1.2 per 100,000 patients. Cervical cancer is a
preventable malignancy because it has long precancerous
conditions, screening programs, and effective treatments
for precancerous lesions (2).
Human Papillomavirus (HPV) has more than 100 geno-
types, at least 12 of which are high-risk and associated with
several cancers (3). Persistent infection with high-risk HPV
types causes cellular abnormalities that can be an impor-
tant precursor for carcinogenesis. The detection of HPV
is a strong predictor of the development of invasive carci-
noma. Human papillomavirus 16 and HPV18 are the most
common genotypes linked to genital cancers. These two
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high-risk types cause about 70% of cervical carcinomas (4).
Cytology testing is commonly used to screen for cer-
vical cancer, although its sensitivity for detecting disease
stages or intraepithelial lesions is not very high. False-
negative results in previous studies have ranged from 15
to 65% (5). Colposcopy is another method for the exami-
nation of the cervix. It has high sensitivity (94%) for detect-
ing the stages of cervical carcinoma. Colposcopy can detect
high-grade cervical intraepithelial neoplasia cases, but its
specificity and reproducibility in women with minor cyto-
logical cervical lesions are not high (less than 50%) (6). Pre-
vious studies indicated that the genome of HPV is present
in more than 90% of cervical carcinoma cases (7). Several
studies have shown that HPV detection is better than cytol-
ogy for the detection of severe cervical lesions. In a study
conducted in Italy with a large sample size, screening with
HPV testing was more effective than common cytology test-
ing in the prevention of invasive cervical carcinoma (8).
Human papillomavirus testing can help detect pre-
cancerous changes that are not clinically visible or de-
tectable by cytology examination. Several studies demon-
strated that combined cytology and HPV testing were not
more effective than sole HPV testing for cervical cancer
screening. Therefore, molecular testing for the detection
and genotyping of HPV in cervical samples can improve the
efficacy of cancer screening (9). The US Preventive Services
Task Force (USPSTF) recommends screening every three
years with cervical cytology alone, every five years with HPV
testing alone, or in combination with cytology testing in
women aged 30 to 65 years (10). It is noticed that the cy-
tology and colposcopy examination may be cheaper than
molecular tests in some countries; therefore, it is more
used for cervical cancer screening (11).
2. Objectives
Data on the prevalence of high-risk HPV genotypes
among women are not yet available for the total regions of
Iran. The present study aimed to determine the prevalence
of high-risk human papillomavirus types among women
screened for cervical carcinoma in Yazd and compare the
cytology, histology, and colposcopy examinations for the
detection of high-grade cervical lesions.
3. Methods
3.1. Patients
This cross-sectional study enrolled 402 women refer-
ring to Gynecology Clinics of Shahid Sadoughi University
of Medical Sciences, Yazd, Iran, between March 2016 and
February 2017. Women with a history of abnormal Pap
smear results, cervical colposcopy/biopsy, malignancy, and
high-risk behaviors were excluded from the study. Demo-
graphic data, including age, number of pregnancies, age at
first intercourse, and duration of marriage, were collected
by a questionnaire. Women were examined by a gynecolo-
gist for genital lesions.
3.2. Human Papillomavirus Detection
Samples of all 402 women were examined by poly-
merase chain reaction (PCR) for detecting the HPV genome.
Viral genomic DNA was isolated from samples using the
AmpliSens® RIBO-prep Nucleic acid extraction kit (Rus-
sia) according to the manufacturer’s recommendation and
was stored at -80°C. The HPV-DNA was detected and geno-
typed by the MolecuTech REBA HPV-ID kit (Molecules and
Diagnostics, Wonju, Korea), which is a PCR-based reverse
blot hybridization assay. This kit could identify 18 high-
risk HPV genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56,
58, 59, 66, 68, 69, and 73), one probable high-risk HPV (34),
and 13 low-risk HPV genotypes (6, 11, 32, 40, 42, 43, 44, 54,
70, 72, 81, 84, and 87). The nested PCR was performed with
MY11 and MY9 primers in step 1, followed by the GP5/GP6
primer pair in step 2, using the Labcycler PCR system (Sen-
soQuest, Germany). Then, PCR products were denatured
with a denaturation solution and added into the mem-
brane strip labeled with HPV genotype-specific probes.
After washing unhybridized PCR products, the alkaline-
phosphatase enzyme reaction was performed, and chro-
mogen was added to develop detection signals. Finally,
the strips were scanned using REBASCAN (YD Diagnostics
Corp).
3.3. Cytology Examination
Cervical cytology specimens were collected using a cy-
tobrush. The cells obtained were spread on two glass slides,
and a common cytological examination with Papanico-
laou staining was carried out. The Smears were seen by an
experienced cytopathologist, and the findings were classi-
fied according to the Bethesda classification system (12).
3.4. Colposcopy
Colposcopy examinations were performed on women
diagnosed with high-risk HPV by a gynecologic oncolo-
gist. The colposcopic findings were graded according to
the Reids Colposcopic index (RCI) (13). Biopsies were taken
from women for histological examinations.
3.5. Histological Examination
Biopsy samples were stained with hematoxylin-eosin
and evaluated by a pathologist. The tissue specimens were
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classified according to the cervical intraepithelial neopla-
sia (CIN) classification system as normal (without dyspla-
sia), low-grade dysplasia (CIN I), moderate dysplasia (CIN
II), high-grade dysplasia (CIN III) (14). The pathologist had
no information about the results of other tests, including
HPV PCR, cytology, and colposcopy.
3.6. Statistical Analysis
The characteristics of the study participants were pre-
sented as numbers and proportions. Statistical analysis
was carried out by SPSS version 18.0 software. The sensi-
tivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), and accuracy were determined for
colposcopy and Pap smear with the biopsy result as the
gold standard. The chi-square test was used for compar-
ing the number of pregnancies between women with and
without HPV. Student’s t-test was performed for comparing
the mean age, age at first intercourse, and duration of mar-
riage between HPV-positive and HPV-negative women. P-
values of less than 0.05 were considered significant.
4. Results
A total of 402 women aged 21 to 39 years with a mean
of 30.82 ± 4.05 years were screened by cytology examina-
tion and HPV typing. The characteristics of the study pop-
ulation and the results of HPV testing are summarized in
Table 1. There was no significant difference in the mean
age, the number of pregnancies, and duration of marriage
between HPV-positive and HPV-negative women (P-value
> 0.05). The HPV-positive women had a lower mean age
at first intercourse than HPV-negative people (P-value <
0.0001).
Thirty-two (7.97%) women were positive for high-risk
HPV types (Table 2), of whom 11 (34.4%) patients were in
the range of 20 - 30 years and 21 patients aged more than
30 years. Besides, HPV16 and HPV18 were the most fre-
quent genotypes detected in participants. One woman was
co-infected with subtypes 16 and 18. The results of Pap
smear, colposcopy, and histology examinations in women
infected with high-risk HPV types are summarized in Table
3. The results of Pap smear were abnormal in 56.2% of HPV-
positive women, and ASCUS was the most common find-
ing (31.2%). Among 32 women with high-risk HPV, 13 peo-
ple had positive colposcopy results. The histology exam-
ination of eight HPV-positive patients showed CIN II and
CIN III, while one woman had CIN I and 23 subjects had nor-
mal tissues. Physical examinations revealed genital warts
in two HPV-positive women and cervical wounds in four pa-
tients, while 26 women had no visible cervical lesions.
Twenty-four women diagnosed with high-risk HPV
types had anal intercourse. Ten women with CIN I or nor-
mal histology examination and eight patients with CIN II
had abnormal Pap smear. Pap smear testing for the detec-
tion of women infected with high-risk types of HPV and
cancerous lesions had 100% sensitivity and 58.3% speci-
ficity, while these values for colposcopy were 75% and 87.5%,
respectively (Table 4). Combined colposcopy/Pap smear ex-
amination did not increase the sensitivity and specificity
of detecting cancerous lesions in high-risk HPV-positive
women compared to the Pap test.
5. Discussion
Human papillomavirus is a sexually transmitted infec-
tious agent that is known as an important risk factor for
developing cervical carcinoma. In the present study, the
prevalence of high-risk HPV types among women living in
Yazd, Iran, was about 8%. Besides, HPV16 and HPV18 were
found in 40.6% of women infected with high-risk types.
Data on the prevalence of high-risk HPV types among
women are not yet available for the total regions of Iran.
The rate of high-risk HPV types in most studies conducted
in Iran has been reported higher than in the present study.
In the study of Yousefzadeh et al. (15), 30.3% of women in
Tehran were infected with high-risk types of HPV, 10.1% of
which were subtypes 16 and 18. High-risk HPV types were
prevalent among 61.3% of HPV-positive women in Kerman-
shah, and types 16 and 18 were detected in 26% of them
(16). The prevalence of HPV genotypes among populations
is varied because of the difference in laboratory tests for
the detection of the virus, such as the used primers in PCR,
the region and geographic locality, age categories, and type
of population (2).
In the current study, Pap smear tests were abnormal in
56.2% of high-risk HPV-positive patients, and 71.9% of HPV-
infected patients had normal histology in biopsy examina-
tions. These results indicate that a significant number of
women were infected with high-risk types of HPV, but they
had normal cytology. They are at risk of developing can-
cer in the coming years. Hopman et al. (17) followed 68
women with normal cervical cytology who were infected
with high-risk HPV types. Seventeen patients developed
abnormal cytology within four years after virus detection,
and high-grade dysplasia was seen in eight women (17). The
HPV screening of women can help decrease the occurrence
of precancerous and cancerous events in the cervix. The re-
sults of the current study highlight the importance of HPV
screening relative to Pap smear for detecting predictable
future cancer events.
In the present study, normal colposcopic results were
obtained in 71.9% of high-risk HPV-positive women. The col-
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Table 1. Characteristics of the Study Population and Results of Human Papillomavirus Testinga
Variable HPV-Positive HPV-Negative Total P-Value
Number of pregnancies 0.441
0 10 76 86
1 13 133 146
2 6 11 17
3 3 44 47
4 0 7 7
Age 31.03 ± 4.95 30. 8 ± 3.97 30.82 ± 4.05 0.760
Age at first intercourse 19.6 ± 2.44 22.1 ± 3.19 21.9 ± 3.21 < 0.0001
Duration of marriage, y 10.03 ± 5.77 8.6 ± 4.18 8.74 ± 4.34 0.080
aValues are expressed as mean ± SD.
Table 2. Human Papillomavirus Types Detected Among the Study Populationa
HPV Type Values
16 5 (15.6)
16 and 18 1 (3.1)
16 and others 7 (21.9)
18 and others 2 (6.3)
Others 17 (53.1)
aValues are expressed as No. (%).
poscopy had 75% sensitivity and 87.5% specificity for the de-
tection of high-grade cervical lesions. Generally, the diag-
nostic sensitivity of CIN 2 or worse lesions by colposcopy
is reported to be 30 - 70% (18). In a study by Zandvakili et
al. (19) conducted in Iran, the sensitivity and specificity
of colposcopy were 69.23% and 73.46%, respectively that
were lower than our results. Zamani et al. (20) also re-
ported a sensitivity of 60% and specificity of 64% for col-
poscopy. The specificity of colposcopy was higher in the
current study than in studies conducted by Zivadinovic et
al. (57%) (21), Adamopoulou et al. (50%) (9), Kohi et al. (57%)
(22), and Ramesh et al. (46%) (23), but its sensitivity was
lower than in the studies mentioned above.
Incompatible with the findings of the present study,
several studies have reported that the sensitivity of col-
poscopy is higher than that of Pap test for the detection
of high-grade cervical lesions (1, 22, 24). In a study con-
ducted in Yazd, Iran, the sensitivity of Pap smear and col-
poscopy was 50% and 80%, respectively, which is in contrast
to our results (25). However, a lower number of high-grade
lesions in the current study than in previous studies may
be a possible reason for the conflicting results. In addition,
the difference in the quality of performing colposcopy and
biopsy may affect the results of studies.







Normal 14 357 371
HSIL 2 0 2
LSIL 4 5 9
ASCUS 10 8 18
ASC-H 2 0 2
Colposcopy
Normal 19 358 377
Low-grade 4 12 16
High-grade 9 0 9
Histology
Normal 23 361 382
CIN I 1 8 9
CIN II 4 1 5
CIN III 4 0 4
Total 32 370 402
5.1. Conclusions
The prevalence of high-risk HPV types was relatively
low among women living in Yazd than in those from other
provinces of Iran. A significant percentage of high-risk
HPV-infected patients had normal cervical cytology and
histology. Therefore, the HPV screening test is recom-
mended to decrease the development of high-grade cervi-
cal lesions and carcinoma. Colposcopy has an acceptable
sensitivity and specificity for the detection of precancer-
ous and cancerous cervical lesions.
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Table 4. Sensitivity, Specificity, Positive Predictive Value, and Negative Predictive Value of Pap Smear, Colposcopy, and Combined Pap Smear/Colposcopy for Detection of Cervical
Lesions in Human Papillomavirus-positive Women
Test Sensitivity, % Specificity, % PPV NPV Accuracy
Pap smear 100 58.3 44.4 100 68.7
Colposcopy 75 87.5 66.7 91.3 84.3
Pap smear and colposcopy 100 58.3 44.4 100 100
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.
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